Meletios Dimopoulos, Adrian Alegre, Edward A. Stadtmauer, Hartmut Goldschmidt, Jeffrey A. Zonder, Carlos M. de Castro, Zvenyslava Masliak, Donna Reece, Marta Olesnyckyj, Zhinuan Yu and Donna M. Weber The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function Cancer 116
Article first published online: 24 MAY 2010 | DOI: 10.1002/cncr.25139
In this retrospective subanalysis of data from 2 large phase 3 studies, the authors evaluated the effect of renal impairment, as defined by calculated creatinine clearance, on the outcomes of patients with relapsed and/or refractory multiple myeloma who received treatment with lenalidomide plus dexamethasone. With careful monitoring of calculated creatinine clearance level and adverse events followed by appropriate dose adjustments, lenalidomide plus dexamethasone was an effective and well tolerated treatment option for multiple myeloma in patients with renal impairment.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field